MedTrace Logo

A Study With Lanadelumab in Persons With Hereditary Angioedema (HAE) in Poland

NCT05147181 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 48

Last updated 2026-03-31

No results posted yet for this study

Summary

The main aim of this study is to learn about how many persons with HAE type I or type II are attack-free when treated with lanadelumab in real life, how many attacks occur and how many of these attacks need rescue treatment and about the nature of HAE attacks.

Participants will need to visit their doctor 5 times in total as part of this study. The visits are planned every 6 months. Participants will also be asked to fill out questionnaires as part of this study.

Conditions

  • Hereditary Angioedema (HAE)

Sponsors & Collaborators

Principal Investigators

  • Study Director · Takeda

Eligibility

Min Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-03-11
Primary Completion
2025-11-13
Completion
2025-11-13

Countries

  • Poland

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05147181 on ClinicalTrials.gov